Quantifying changes in local basal ganglia structural connectivity in the 6-hydroxydopamine model of Parkinson's Disease using correlational tractography

被引:0
|
作者
Moshchin, Mikhail [1 ]
Cheng, Kevin P. [1 ]
Osting, Susan [1 ]
Laluzerne, Matthew [1 ]
Hurley, Samuel A. [1 ]
Singh, Ajay Paul [1 ]
Trevathan, James K. [1 ]
Brzeczkowski, Andrea [1 ]
Yu, John-Paul J. [1 ]
Lake, Wendell B. [1 ]
Ludwig, Kip A. [1 ]
Suminski, Aaron J. [1 ]
机构
[1] Univ Wisconsin Madison, Madison, WI 53706 USA
关键词
Parkinson's disease; 6-OHDA; ex-vivo magnetic resonance imaging; diffusion tensor imaging; quantitative anisotropy; deterministic tractography; DEGENERATION; DOPAMINE;
D O I
10.1109/NER52421.2023.10123839
中图分类号
TP18 [人工智能理论];
学科分类号
081104 ; 0812 ; 0835 ; 1405 ;
摘要
In recent years, tractography based on diffusion magnetic resonance imaging (dMRI) has become a popular tool for studying microstructural changes resulting from brain diseases like Parkinson's Disease (PD). Quantitative anisotropy (QA) is a parameter that is used in deterministic fiber tracking as a measure of connection between brain regions. It remains unclear, however, if microstructural changes caused by lesioning the median forebrain bundle (MFB) to create a Parkinsonian rat model can be resolved using tractography based on ex-vivo diffusion MRI. This study aims to fill this gap and enable future mechanistic research on structural changes of the whole brain network rodent models of PD. Specifically, it evaluated the ability of correlational tractography to detect structural changes in the MFB of 6-hydroxydopamine (6-OHDA) lesioned rats. The findings reveal that correlational tractography can detect structural changes in lesioned MFB and differentiate between the 6-OHDA and control groups. Imaging results are supported by behavioral and histological evidence demonstrating that 6-OHDA lesioned rats were indeed Parkinsonian. The results suggest that QA and correlational tractography is appropriate to examine local structural changes in rodent models of neurodegenerative disease. More broadly, we expect that similar techniques may provide insight on how disease alters structure throughout the brain, and as a tool to optimize therapeutic interventions.
引用
收藏
页数:4
相关论文
共 50 条
  • [1] The 6-hydroxydopamine model of Parkinson's disease
    Simola, Nicola
    Morelli, Micaela
    Carta, Anna R.
    NEUROTOXICITY RESEARCH, 2007, 11 (3-4) : 151 - 167
  • [2] The 6-Hydroxydopamine model of parkinson’s disease
    Nicola Simola
    Micaela Morelli
    Anna R. Carta
    Neurotoxicity Research, 2007, 11 : 151 - 167
  • [3] The 6-hydroxydopamine Rat Model of Parkinson's Disease
    Guimaraes, Rayanne Poletti
    Ribeiro, Danilo Leandro
    dos Santos, Keila Bariotto
    Godoy, Livea Dornela
    Correa, Mirella Rosine
    Padovan-Neto, Fernando Eduardo
    JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2021, (176):
  • [4] Behavioural effects of basal ganglia rho-kinase inhibition in the unilateral 6-hydroxydopamine rat model of Parkinson’s disease
    Salim Yalcin Inan
    Burak Cem Soner
    Ayse Saide Sahin
    Metabolic Brain Disease, 2016, 31 : 849 - 857
  • [5] Bilateral changes in neuronal activity of the basal ganglia in the unilateral 6-hydroxydopamine rat model
    Breit, S.
    Martin, A.
    Lessmann, L.
    Cerkez, D.
    Gasser, T.
    Schulz, J. B.
    JOURNAL OF NEUROSCIENCE RESEARCH, 2008, 86 (06) : 1388 - 1396
  • [6] Erratum to: Behavioural effects of basal ganglia rho-kinase inhibition in the unilateral 6-hydroxydopamine rat model of Parkinson’s disease
    Salim Yalcin Inan
    Burak Cem Soner
    Ayse Saide Sahin
    Metabolic Brain Disease, 2016, 31 : 859 - 859
  • [7] Neuroprotection by safinamide in the 6-hydroxydopamine model of Parkinson's disease
    Sadeghian, M.
    Mullali, G.
    Pocock, J. M.
    Piers, T.
    Roach, A.
    Smith, K. J.
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2016, 42 (05) : 423 - 435
  • [8] Molecular Profiling of a 6-Hydroxydopamine Model of Parkinson’s Disease
    Sang J. Na
    Anthony G. DiLella
    Edward V. Lis
    Keith Jones
    David M. Levine
    David J. Stone
    J. F. Hess
    Neurochemical Research, 2010, 35 : 761 - 772
  • [9] Neuroprotection of edaravone in a 6-hydroxydopamine model of Parkinson's disease
    Li, G.
    Tian, J.
    MOVEMENT DISORDERS, 2006, 21 : S344 - S345
  • [10] Molecular Profiling of a 6-Hydroxydopamine Model of Parkinson's Disease
    Na, Sang J.
    DiLella, Anthony G.
    Lis, Edward V.
    Jones, Keith
    Levine, David M.
    Stone, David J.
    Hess, J. F.
    NEUROCHEMICAL RESEARCH, 2010, 35 (05) : 761 - 772